Centogene N.V. (Nasdaq: CNTG), the essential life science partner
for data-driven answers in rare and neurodegenerative diseases,
today announced the global launch of its Biodata Network, a
portfolio of data-driven partnering solutions, including Biodata
Licenses and Insight Reports, for biopharma and research
institutions.
To offer increased access to CENTOGENE’s unique
data-driven insights, the Company has partnered with BC Platforms,
a global leader in healthcare data management and analytics, to
utilize their Global Data Partner Network, BCRQUEST.com. This
integrated healthcare data platform creates a connected, secure
data source for enabling partners access to datasets for the
acceleration and de-risking of target & drug discovery, as well
as for optimizing clinical pipelines.
The addition of these CENTOGENE datasets
represents an estimated 20% increase in both the breadth and depth
of genomic data currently available via BC Platforms. The dataset
reflects a diverse geographic and ethnic sample base and includes a
large share of pediatric cases in rare and neurodegenerative
diseases, with data modalities including clinical, multiomic, and
socio-demographic data. This dataset has been made available from
the diverse CENTOGENE Biodatabank, which currently contains nearly
700,000 patients represented from over 120 countries, over 70% of
whom are of non-European descent.
“At CENTOGENE, we are committed to delivering
data-driven, life-changing answers to accelerate and de-risk drug
discovery, development, and commercialization,” said Kim Stratton,
Chief Executive Officer at CENTOGENE. “By partnering with BC
Platforms and launching our Biodata Network Portfolio, we are
extending our strategy and expanding our commercialization
opportunities to provide partners with yet another model to work
with us. Ultimately, we want to heal the world of rare and
neurodegenerative diseases, and we believe offering greater access
to the CENTOGENE Biodatabank will accelerate bringing potentially
life-saving therapeutics to patients around the world.”
Tero Silvola, CEO of BC Platforms, said,
“Through our partnership with CENTOGENE, one of the most
experienced partners in the field, we are significantly advancing
the way the medical community collaborates. With the diversity of
our BCRQUEST.com global data network combined with CENTOGENE’s
Biodatabank, the medical community will now be able to tap into a
rich source of insights on rare and neurodegenerative diseases to
drive the healthcare of the future – benefitting patients
globally.”
Bettina Goerner, CENTOGENE’s Chief Data Officer,
added, “95% of rare diseases currently do not have an FDA-approved
treatment. We see BC Platforms as our ideal partner for the secure
and scalable solutions needed for the launch of our Biodata
Network, so we can significantly expand the abilities of our
partners around the world to drive drug discovery. Because of the
generous consent given by patients who have contributed their data
for research on rare and neurodegenerative diseases, we hope to
offer real solutions to patients around the world.”
CENTOGENE has a life-long commitment to
protecting the privacy of patients’ data, which is secured and
handled with the greatest level of care and in accordance with
applicable regulations and laws, including but not limited to,
GDPR. Every year, CENTOGENE processes thousands of genetic tests in
the Company’s state-of-the-art laboratories, while ensuring
relevant compliances.
The CENTOGENE Biodata Network –
Transforming Insights Into Answers
CENTOGENE’s newly-launched Biodata Network
portfolio of customizable data-driven partnering solutions
includes:
Biodata Licenses
- Biodata Licenses enable partners to
securely access unique real-world datasets via BC Platform’s
cloud-based trusted research environment for self-analysis.
Optional analysis support is also available
Insight Reports
- These tailored data analysis reports
are generated in close consultation with biopharma partners and
CENTOGENE’s in-house geneticists, medical experts, and data
scientists. This seamlessly enables institutions to answer ad hoc
research questions via real-world data, which is carefully curated,
analyzed, and summarized by CENTOGENE’s team of experts
About
CENTOGENE
CENTOGENE’s mission is to provide data-driven,
life-changing answers to patients, physicians, and biopharma
companies for rare and neurodegenerative diseases. We integrate
multiomic technologies with the CENTOGENE Biodatabank – providing
dimensional analysis to guide the next generation of precision
medicine. Our unique approach enables rapid and reliable diagnosis
for patients, supports a more precise physician understanding of
disease states, and accelerates and de-risks targeted biopharma
drug discovery, development, and commercialization.
Since our founding in 2006, CENTOGENE has been
offering rapid and reliable diagnosis – building a network of
approximately 30,000 active physicians. Our ISO, CAP, and CLIA
certified multiomic reference laboratories in Germany utilize
Phenomic, Genomic, Transcriptomic, Epigenomic, Proteomic, and
Metabolomic datasets. This diverse data is captured in our
CENTOGENE Biodatabank, with nearly 700,000 patients represented
from over 120 countries, over 70% of whom are of non-European
descent. To date, the CENTOGENE Biodatabank has contributed to
generating novel insights for more than 260 peer-reviewed
publications.
By translating our data and expertise into
tangible insights, we have supported over 50 collaborations with
biopharma partners. Together, we accelerate and de-risk drug
discovery, development, and commercialization in target & drug
screening, clinical development, market access and expansion, as
well as offering Biodata Licenses and Insight Reports to enable a
world healed of all rare and neurodegenerative diseases.
To discover more about our products, pipeline,
and patient-driven purpose, visit www.centogene.com and follow us
on LinkedIn.
About BC Platforms
BC Platforms is a global leader in building data
networks for the life sciences industry and provides versatile
technology platforms for personalised medicine, accelerating the
translation of innovations into clinical practice. We convert
complex biological information collected in the healthcare setting
into actionable insights. With our innovative technology we are
creating a patient centric infinity loop between the life sciences
and healthcare sectors. Data we generate, harmonise, and manage,
from diverse biobanks and healthcare institutions, is made
accessible for pharmaceutical and biotech companies to enhance
their core strengths in research and development. In parallel, we
enable stratification of patients towards targeted therapies,
delivering on the promise of more personalized healthcare.
Our high performing genomic data discovery and
analytics platform enables flexible data integration, secure
analysis, and interpretation of molecular and clinical information.
We have developed a Global Data Partner Network, BCRQUEST.com,
which allows access to high-quality real-world data. This rapidly
growing network has a footprint across many sites, including
networks of major hospitals, covering 20 countries on five
continents, providing standard of care data for over 23 million
patients. Our platforms seamlessly facilitate access to highly
enriched data for pharmaceutical research and development.
Founded in 1997 from a MIT Whitehead project
spinoff, we have a strong scientific heritage underpinned by over
25 years of working in close collaboration with a network of
leading researchers, developers, and industry partners. We have
global operations with our headquarters in Zurich, Switzerland,
R&D in Espoo, Finland, and Singapore, as well as a presence in
London and Boston. For more information, visit our website and
follow us on LinkedIn.
Forward-Looking Statements
This press release contains “forward-looking
statements” within the meaning of the U.S. federal securities laws.
Statements contained herein that are not clearly historical in
nature are forward-looking, and the words “anticipate,” “believe,”
“continues,” “expect,” “estimate,” “intend,” “project,” and similar
expressions and future or conditional verbs such as “will,”
“would,” “should,” “could,” “might,” “can,” and “may,” are
generally intended to identify forward-looking statements. Such
forward-looking statements involve known and unknown risks,
uncertainties, and other important factors that may cause
CENTOGENE’s actual results, performance, or achievements to be
materially different from any future results, performance, or
achievements expressed or implied by the forward-looking
statements. Such risks and uncertainties include, among others,
negative economic and geopolitical conditions and instability and
volatility in the worldwide financial markets, possible changes in
current and proposed legislation, regulations and governmental
policies, pressures from increasing competition and consolidation
in our industry, the expense and uncertainty of regulatory
approval, including from the U.S. Food and Drug Administration, our
reliance on third parties and collaboration partners, including our
ability to manage growth and enter into new client relationships,
our dependency on the rare disease industry, our ability to manage
international expansion, our reliance on key personnel, our
reliance on intellectual property protection, fluctuations of our
operating results due to the effect of exchange rates, our ability
to streamline cash usage, our requirement for additional financing,
or other factors. For further information on the risks and
uncertainties that could cause actual results to differ from those
expressed in these forward-looking statements, as well as risks
relating to CENTOGENE’s business in general, see CENTOGENE’s risk
factors set forth in CENTOGENE’s Form 20-F filed on March 31, 2022,
with the Securities and Exchange Commission (the “SEC”) and
subsequent filings with the SEC. Any forward-looking statements
contained in this press release speak only as of the date hereof,
and CENTOGENE’s specifically disclaims any obligation to update any
forward-looking statement, whether as a result of new information,
future events, or otherwise.
Media Contact:
CENTOGENE Ben
Legg Corporate Communications Press@centogene.com
Centogene NV (NASDAQ:CNTG)
Historical Stock Chart
From Aug 2024 to Sep 2024
Centogene NV (NASDAQ:CNTG)
Historical Stock Chart
From Sep 2023 to Sep 2024